Literature DB >> 26414224

Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations.

Seiji Yamada1, Benjamin R Kipp, Jesse S Voss, Caterina Giannini, Aditya Raghunathan.   

Abstract

Pleomorphic xanthoastrocytoma (PXA) has rarely been reported in combination with infiltrating glioma, historically interpreted as a "collision tumor." Isocitrate dehydrogenase 1 (IDH1) and BRAF V600E mutations are usually not concurrent. The former is typical of adult infiltrating gliomas, and the latter is identified in a variety of primary central nervous system neoplasms, including PXA, ganglioglioma, pilocytic astrocytoma, and rarely infiltrating gliomas. We report the case of a 56-year-old man presenting with seizures and headaches. Magnetic resonance imaging revealed a large right temporal lobe mass with low T1 and high T2/FLAIR signal and a discrete contrast-enhancing focus. Histologically, the tumor showed 2 distinct components: an infiltrating astrocytoma harboring 5 mitoses/10 high-power fields and a relatively circumscribed focus, resembling PXA with, at most, 2 mitoses/10 high-power fields. No microvascular proliferation or necrosis was present in either component. The infiltrating astrocytoma component contained numerous axons, whereas the PXA-like component had sparse axons, as demonstrated by the neurofilament immunostain. Both components were positive for the mutant IDH1 R132H and showed loss of ATRX expression, whereas BRAF V600E was restricted to the PXA-like component. On sequencing of the 2 components separately after microdissection, both showed identical IDH1 R132H and TP53 R273C point mutations, whereas the BRAF V600E mutation was limited to the PXA-like component. These findings are consistent with clonal expansion of a morphologically distinct focus, harboring a private BRAF V600E mutation within an IDH1-mutant glioma. Intratumoral heterogeneity and clonal evolution, as seems to have occurred here, suggest reevaluation of "collision tumors" as a concept.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26414224     DOI: 10.1097/PAS.0000000000000515

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  4 in total

1.  Impact of WHO 2016 update of brain tumor classification, molecular markers and clinical outcomes in pleomorphic xanthoastrocytoma.

Authors:  Raees Tonse; Tejpal Gupta; Sridhar Epari; Jayant Goda Shastri; Mamta Gurav; Nazia Bano; Rakesh Jalali
Journal:  J Neurooncol       Date:  2017-11-16       Impact factor: 4.130

Review 2.  Pathologic and molecular aspects of anaplasia in circumscribed gliomas and glioneuronal tumors.

Authors:  Elisabet Pujadas; Liam Chen; Fausto J Rodriguez
Journal:  Brain Tumor Pathol       Date:  2019-03-11       Impact factor: 3.298

3.  Assessment of genetic variant burden in epilepsy-associated brain lesions.

Authors:  Lisa-Marie Niestroj; Patrick May; Mykyta Artomov; Katja Kobow; Roland Coras; Eduardo Pérez-Palma; Janine Altmüller; Holger Thiele; Peter Nürnberg; Costin Leu; Aarno Palotie; Mark J Daly; Karl Martin Klein; Rudi Beschorner; Yvonne G Weber; Ingmar Blümcke; Dennis Lal
Journal:  Eur J Hum Genet       Date:  2019-07-29       Impact factor: 4.246

Review 4.  Angiomatous pleomorphic xanthoastrocytoma: a case report and literature review.

Authors:  Yue-Feng Jiang; Yang Liu; Ye-Lin Wang; Hong-Yi Cao; Liang Wang; Hong-Tao Xu; Qing-Chang Li; Xue-Shan Qiu; En-Hua Wang
Journal:  Diagn Pathol       Date:  2016-08-09       Impact factor: 2.644

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.